HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...

Gilead Sciences Inc (GILD.O) and rival Merck & Co Inc (MRK.N) said on Monday they will test a combination of their experimental HIV drugs to develop a long-acting treatment for the infection that ...

Merck (NYSE:MRK) has acquired late-stage and early stage drugs to treat HIV infection in two separate licensing deals, with one valued at more than $168 million. Read more.

Gilead Sciences and Merck announced a partnership to codevelop lenacapavir and islatravir as a long-acting two-drug regimen for patients with HIV. News News CME CME ...

Merck (NYSE:MRK) recently announced the initiation of its Phase 3 EXPrESSIVE clinical trials for MK-8527, a new HIV prevention drug, reflecting its commitment to addressing global health challenges.

News of trouble at Merck emerged last month when the company paused development of an asset, MK-8507, that was central to its plans to create an oral, once-weekly treatment for HIV patients.

RELATED: Merck pauses 2 more trials of backbone HIV drug over red flag, raising doubts about multipronged R&D strategy The New Jersey Pharma said the FDA's decision was based on decreases in total ...

Merck, known as MSD outside the United States and Canada, announced today upcoming presentations from its HIV clinical development programs that will be featured during the 2021 Conference on ...

Gilead Sciences Inc and rival Merck & Co Inc said on Monday they will test a combination of their experimental HIV drugs to develop a long-acting treatment for the infection that affects millions ...

Rivals Gilead Sciences Inc.GILD1.81%increase; green up pointing triangle and Merck MRK 1.74%increase; green up pointing triangle & Co. are joining forces to develop a long-acting HIV therapy, the ...